Manumycin A
(Synonyms: 手霉素A) 目录号 : GC10265A farnesyltransferase inhibitor with antitumor activity
Cas No.:52665-74-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Manumycin A is an antibiotic that act as a potent and selective farnesyltransferase inhibitor [1]．
Farnesyltransferase posttranslationally-modifies proteins by adding a farnesyl group to the -SH of the cysteine near the end of target proteins to form a thioether linkage. Farnesylation makes become membrane-associated.
Manumycin A is a potent and selective ras farnesyltransferase inhibitor. In cultured MB cells, Manumycin A (≥10 ?M) blocked p21 ras farnesylation and induced apoptosis [1]. In rat VSMCs, Manumycin A signi?cantly consistently inhibited [3H]-thymidine incorporation in a dose-dependent way and inhibited cell growth. In a trans-well assay, manumycin A (50 ng/ml) inhibited VSMC migration in the presence of 10 ng/ml of PDGF [2].
In myotonic dystrophy type 1 (DM1) mice with 250 CUG repeats, Manumycin A significantly reduced Clcn1 exon 7A inclusion and corrected aberrant splicing of Clcn1 [3].
References:
[1].Wang W, Macaulay RJ. Apoptosis of medulloblastoma cells in vitro follows inhibition of farnesylation using manumycin A. Int J Cancer. 1999 Jul 30;82(3):430-4.
[2].Kouchi H, Nakamura K, Fushimi K, et al. Manumycin A, inhibitor of ras farnesyltransferase, inhibits proliferation and migration of rat vascular smooth muscle cells. Biochem Biophys Res Commun. 1999 Nov 2;264(3):915-20.
[3].Oana K, Oma Y, Suo S, et al. Manumycin A corrects aberrant splicing of Clcn1 in myotonic dystrophy type 1 (DM1) mice. Sci Rep. 2013;3:2142
.
| Cas No. | 52665-74-4 | SDF | |
| 别名 | 手霉素A | ||
| 化学名 | (R,2Z,4E)-N-((1S,5S,6R)-5-hydroxy-5-((1E,3Z,5Z)-7-((2-hydroxy-5-oxocyclopent-1-en-1-yl)amino)-7-oxohepta-1,3,5-trien-1-yl)-2-oxo-7-oxabicyclo[4.1.0]hept-3-en-3-yl)-2,4,6-trimethyldeca-2,4-dienamide | ||
| Canonical SMILES | CCCC[C@H](/C=C(/C=C(C(NC1=C[C@@](/C=C/C=C\C=C/C(NC2=C(CCC2=O)O)=O)([C@@H]3O[C@@H]3C1=O)O)=O)/C)C)C | ||
| 分子式 | C31H38N2O7 | 分子量 | 550.64 |
| 溶解度 | DMF: 20 mg/ml,DMF:PBS (pH 7.2) (1:1): 0.5 mg/ml,DMSO: 10 mg/ml,Ethanol: 5 mg/ml | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.8161 mL | 9.0803 mL | 18.1607 mL |
| 5 mM | 0.3632 mL | 1.8161 mL | 3.6321 mL |
| 10 mM | 0.1816 mL | 0.908 mL | 1.8161 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。